Cargando…

Real life persistence rate with antimuscarinic treatment in patients with idiopathic or neurogenic overactive bladder: a prospective cohort study with solifenacin

BACKGROUND: Several studies have shown that the antimuscarinic treatment of overactive bladder is characterized by low long-term persistence rates. We have investigated the persistence of solifenacin in real life by means of telephonic interviews in a prospective cohort. We included both patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tijnagel, Marloes J., Scheepe, Jeroen R., Blok, Bertil F. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5390358/ https://www.ncbi.nlm.nih.gov/pubmed/28403849 http://dx.doi.org/10.1186/s12894-017-0216-4

Ejemplares similares

Antimuscarinics for neurogenic overactive bladder in multiple sclerosis: real-life data
por: Andretta, Elena, et al.
Publicado: (2022)

Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivity
por: Tannenbaum, Stacey, et al.
Publicado: (2020)

Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK
por: Hakimi, Zalmai, et al.
Publicado: (2018)

Comparison of solifenacin and fesoterodine in treatment of overactive bladder
por: Ercan, Önder, et al.
Publicado: (2015)

An Overview of the Clinical Use of Antimuscarinics in the Treatment of Overactive Bladder
por: Athanasopoulos, Anastasios, et al.
Publicado: (2011)

Solifenacin in Multiple Sclerosis Patients with Overactive Bladder: A Prospective Study
por: van Rey, Farida, et al.
Publicado: (2011)

Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review
por: Yeowell, Gillian, et al.
Publicado: (2018)

Efficacy and tolerability of mirabegron compared with solifenacin for children with idiopathic overactive bladder: A preliminary study
por: Kim, Seong Cheol, et al.
Publicado: (2021)

Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: Findings from the PERSPECTIVE registry study
por: Carlson, Kevin V., et al.
Publicado: (2021)

Solifenacin significantly improves all symptoms of overactive bladder syndrome
por: CHAPPLE, C R, et al.
Publicado: (2006)

Acute effect of sacral neuromodulation for treatment of detrusor overactivity on urodynamic parameters
por: Groenendijk, Ilse M., et al.
Publicado: (2019)

Transcutaneous Electrical Stimulation of the Abdomen, Ear, and Tibial Nerve Modulates Bladder Contraction in a Rat Detrusor Overactivity Model: A Pilot Study
por: Coolen, Rosa L., et al.
Publicado: (2023)

Clinical Factors Associated With Dose Escalation of Solifenacin for the Treatment of Overactive Bladder in Real Life Practice
por: Chun, Ji-Youn, et al.
Publicado: (2014)

A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain
por: Nazir, Jameel, et al.
Publicado: (2018)

Choice of antimuscarinic agents for overactive bladder in the older patient: focus on darifenacin
por: Chughtai, Bilal, et al.
Publicado: (2008)

Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK
por: Nazir, Jameel, et al.
Publicado: (2017)

Tamsulosin and Solifenacin in the Treatment of Benign Prostatic Hyperplasia in combination with overactive bladder
por: Wang, Hui, et al.
Publicado: (2017)

Editorial Comment: Solifenacin treatment after intradetrusor injections with botulinum toxin in patients with neurogenic detrusor overactivity
por: Averbeck, Marcio Augusto
Publicado: (2022)

A Comparative Study of Solifenacin, Mirabegron, and Their Combination as Bladder Relaxants in the Management of Overactive Bladder
por: Kumar, Shailendra, et al.
Publicado: (2023)

A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder
por: Lee, Soyon, et al.
Publicado: (2009)

Clinical Efficacy of Solifenacin in the Management of Diabetes Mellitus-Associated Versus Idiopathic Overactive Bladder Symptoms: A Multicenter Prospective Study
por: Choi, Hoon, et al.
Publicado: (2018)

Meta-Analysis of the Efficacy and Safety of Mirabegron Add-On Therapy to Solifenacin for Overactive Bladder
por: Xu, Yankai, et al.
Publicado: (2017)

Effectiveness of antimuscarinics and a beta-3 adrenoceptor agonist in patients with overactive bladder in a real-world setting
por: Huang, Chiung-Kun, et al.
Publicado: (2020)

Exposure to antimuscarinic medications for treatment of overactive bladder and risk of lung cancer and colon cancer
por: Löfling, Lukas, et al.
Publicado: (2019)

Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom
por: Margulis, Andrea V., et al.
Publicado: (2018)

Cost Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in Colombia
por: Parise, Hélène, et al.
Publicado: (2019)

Comparison of antimuscarinic drugs to beta adrenergic agonists in overactive bladder: A literary review
por: Wani, Mudassir M., et al.
Publicado: (2021)

Mirabegron and antimuscarinic use in frail overactive bladder patients in the United States Medicare population
por: Johnson, Theodore M., et al.
Publicado: (2022)

Intradetrusor Injections of Onabotulinum Toxin-A in Children With Urinary Incontinence due to Neurogenic Detrusor Overactivity Refractory to Antimuscarinic Treatment
por: Tarcan, Tufan, et al.
Publicado: (2014)

Pooled solifenacin overactive bladder trial data: Creation, validation and analysis of an integrated database
por: Chapple, Christopher R., et al.
Publicado: (2016)

Solifenacin versus posterior tibial nerve stimulation for overactive bladder in patients with multiple sclerosis
por: Majdinasab, Nastaran, et al.
Publicado: (2023)

Efficacy and Tolerability of Solifenacin 5 mg Fixed Dose in Korean Children with Newly Diagnosed Idiopathic Overactive Bladder: a Multicenter Prospective Study
por: Lee, Sang Don, et al.
Publicado: (2017)

Adverse Event Assessment of Antimuscarinics for Treating Overactive Bladder: A Network Meta-Analytic Approach
por: Kessler, Thomas M., et al.
Publicado: (2011)

Maintenance of the Therapeutic Effect of Two High-Dosage Antimuscarinics in the Management of Overactive Bladder in Elderly Women
por: Kosilov, Kirill, et al.
Publicado: (2013)

Antimuscarinic Agent Treatment Affecting Patient-Reported Outcomes in Overactive Bladder Syndrome With Depressive Symptoms
por: Kim, Kyu Shik, et al.
Publicado: (2016)

Antimuscarinic Discontinuation in Patients with Overactive Bladder in Nursing Homes: A Retrospective Study of Medicare Beneficiaries
por: Aparasu, Rajender R., et al.
Publicado: (2020)

Systematic review and meta-analysis of the efficacy and safety of vibegron vs antimuscarinic monotherapy for overactive bladder
por: Su, Shunye, et al.
Publicado: (2021)

Comparative study of different combinations of mirabegron and antimuscarinics in treatment for overactive bladder syndrome in elderly patients
por: Kuo, Yuh-Chen, et al.
Publicado: (2021)

Influence of Daytime or Nighttime Dosing with Solifenacin for Overactive Bladder with Nocturia: Impact on Nocturia and Sleep Quality
por: Kwon, Taekmin, et al.
Publicado: (2017)

Efficacy, according to urodynamics, of OnabotulinumtoxinA compared with antimuscarinic drugs, for neurogenic detrusor overactivity: a systematic review and network meta-analysis
por: Xu, Rui, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g7csnmqu5qccv1nnp1i6ij9gfa